Clinical Trial

A Targeted Amino Acid Supplement for People With Parkinson's Disease

Completed Early Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if an amino acid supplement that is specifically made for people with Parkinson disease can improve nutrition without interfering with dopamine medication in people living with Parkinson disease. The main question it aims to answer is: • Does an amino acid supplement that is specifically made for people with Parkinson disease have short-term improvements in nutrition deficiencies, while minimally interfering with Parkinson disease medication? Researchers will compare the short-term effects of this specialized nutrition supplement to a supplement that is available for everyone to purchase in a store (whey protein supplement-a milk by-product) and to an inactive supplement. Researchers will then check for the indicators of nutrition levels and the presence of dopamine medication in the blood. Researchers will also assess mood and movement abilities in participants. Participants will be asked to: * attend 4 study visits over the course of 4 weeks (initial orientation visit plus 3 intervention visits). * drink one of the 3 supplements (supplements will be mixed into water to create a beverage) at each of the 3 intervention visits. * participate in blood drawings and mood and movement assessments at each of the intervention visits. * engage in a phone call after each intervention visit to determine any delayed responses.
Protocol Amendment History 4 changes
critical Trial completed 2026-08-14
notable Enrollment reduced: 15 -> 3 participants 2026-08-14
notable Primary completion moved earlier: 2025-09 -> 2025-07-17 2026-08-14
minor Completion moved earlier: 2025-09 -> 2025-07-17 2026-08-14
Trial Details
NCT Number NCT06954662
Lead Sponsor UConn Health
Conditions Parkinson Disease, Idiopathic
Enrollment 3 participants
Start Date 2025-05-22
Primary Completion 2025-07-17 (estimated)
Study Completion 2025-07-17 (estimated)
Updated on ClinicalTrials.gov 2026-08-13